Recovery · Reference
KLOW vs GLOW: The One Difference, and How Both Compare to BPC-157 + TB-500 and GHK-Cu
This page explains what each blend contains, what KPV adds and what it does not, how both compare with the two-peptide BPC-157 + TB-500 stack and with GHK-Cu on its own, what the research does and does not show, where each component stands with the FDA, how each is dosed, what each costs at Pepti, and who tends to suit which.
Medically reviewed by Dr. Gene, MD · November 4, 2026
KLOW and GLOW are the same blend with one difference: KLOW adds KPV. Both contain 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 in a 5 mL vial; KLOW adds 10 mg of KPV, a three-amino-acid fragment of alpha-MSH described in animal and cell work as an anti-inflammatory signal. GLOW suits a repair and skin goal on its own; KLOW suits the same goal when persistent inflammation is part of the picture. Both are prescription-only, compounded by a licensed US pharmacy, and neither is FDA approved.
This page explains what each blend contains, what KPV adds and what it does not, how both compare with the two-peptide BPC-157 + TB-500 stack and with GHK-Cu on its own, what the research does and does not show, where each component stands with the FDA, how each is dosed, what each costs at Pepti, and who tends to suit which.
KLOW vs GLOW
The short answer
| If your main goal is | The usual prescription | What is in it | Price |
|---|---|---|---|
| Repair and skin, with inflammation that will not settle | KLOW | 50 mg GHK-Cu, 10 mg KPV, 10 mg BPC-157, 10 mg TB-500 in 5 mL | $259/mo |
| Repair and skin, without an inflammation focus | GLOW | 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 in 5 mL | $259/mo |
| A tendon or ligament injury, nothing else | BPC-157 + TB-500 | 5 mg BPC-157, 5 mg TB-500 in 5 mL | $259/mo |
| Skin or connective-tissue quality only | GHK-Cu | 50 mg GHK-Cu in 5 mL | $239/mo |
| Inflammation without a specific injury | KPV | 10 mg KPV in 5 mL | $229/mo |
| A gut complaint | BPC-157 | 5 mg BPC-157 in 5 mL | $209/mo |
Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee. KLOW and GLOW are the same price at Pepti, so the choice between them is about whether KPV belongs in your vial, not about cost. Current pricing always lives on each product page.
KLOW vs GLOW
GLOW on its own terms
What it is
GLOW is three independently studied peptides dissolved together in one sterile multi-dose vial: GHK-Cu, BPC-157 and TB-500. The name is a brand name for the combination; it does not appear in any journal, and the three-peptide combination has never been studied as a combination. The full reference is at what is GLOW.
Component Per vial What it is Described in research around GHK-Cu 50 mg Copper-binding tripeptide found in human plasma Collagen and elastin synthesis, matrix remodelling BPC-157 10 mg 15-amino-acid fragment of a protein from human gastric juice Angiogenesis, cell migration, gut-lining protection TB-500 10 mg Synthetic fragment of thymosin beta-4 Actin binding and cell movement into damaged tissue Why these three
The rationale prescribers give is that tissue repair runs in overlapping phases, and each component is described in animal and cell work as acting on a different one: BPC-157 on blood supply and cell migration, TB-500 on cell motility, GHK-Cu on collagen and matrix. GHK-Cu is 50 of the 70 mg in the vial, so by mass GLOW is mostly a GHK-Cu preparation with two smaller repair components alongside it. That is why it is positioned toward skin and connective tissue as much as toward injury.
What it leaves out
GLOW has no dedicated anti-inflammatory component. That gap is the entire difference between GLOW and KLOW.
KLOW vs GLOW
KLOW on its own terms
What it is
KLOW is GLOW plus KPV: the same 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500, with 10 mg KPV added, 80 mg in total. Like GLOW, the four-peptide combination has never been studied as a blend; the evidence is per component. The full reference is at what is KLOW.
What KPV adds
KPV is lysine, proline and valine, the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH does two separate things: it drives pigmentation, and it acts as an anti-inflammatory signal. The isolated tripeptide is reported to keep the anti-inflammatory activity and lose the pigmentation effect, which is why KPV is not expected to darken skin.
- Inside the cell. A 2008 paper in Gastroenterology reported that KPV is carried into intestinal cells by the PepT1 transporter and reduced inflammation in mouse colitis models.
- NF-kB and cytokines. Cell and animal studies describe KPV interfering with NF-kB signalling and lowering output of TNF-alpha, IL-6 and other pro-inflammatory cytokines.
- The wider literature. A 2008 review in Endocrine Reviews covers alpha-MSH and its C-terminal tripeptide in models of inflammation.
In KLOW, the logic is that inflammation which never resolves is the commonest reason a repair phase stalls. KPV is there for that phase; the other three are there for the rest. The full reference is at what is KPV.
What KPV does not add
KPV has no human trials of any kind. Its evidence is cell and mouse work, mostly in gut inflammation models. It does not add anything to the skin and collagen side of the blend, and it does not change the amount of any other component.
KLOW vs GLOW
Head to head: KLOW, GLOW, the stack and GHK-Cu
| KLOW | GLOW | BPC-157 + TB-500 | GHK-Cu | |
|---|---|---|---|---|
| Components | GHK-Cu, KPV, BPC-157, TB-500 | GHK-Cu, BPC-157, TB-500 | BPC-157, TB-500 | GHK-Cu |
| Total per 5 mL vial | 80 mg | 70 mg | 10 mg | 50 mg |
| Per 0.25 mL dose | 2.5 mg GHK-Cu, 0.5 mg KPV, 0.5 mg BPC-157, 0.5 mg TB-500 | 2.5 mg GHK-Cu, 0.5 mg BPC-157, 0.5 mg TB-500 | 0.25 mg BPC-157, 0.25 mg TB-500 | 2.5 mg GHK-Cu |
| Dedicated anti-inflammatory component | Yes, KPV | No | No | No |
| Skin and matrix component | Yes | Yes | No | Yes |
| Standard directions | 0.25 mL weekday mornings | 0.25 mL weekday mornings | 0.25 mL weekday mornings | 0.25 mL once daily, Monday to Friday |
| Doses per vial | 20 | 20 | 20 | 20 |
| Formats at Pepti | Vial, or pre-filled Pen | Vial | Vial, or pre-filled Pen | Vial |
| Price at Pepti | $259 a month | $259 a month | $259 a month | $239 a month |
What the numbers show
Three things stand out. First, KLOW and GLOW deliver exactly the same amount of GHK-Cu, BPC-157 and TB-500 per dose; adding KPV does not dilute the other three. Second, the two-peptide stack delivers half as much BPC-157 and TB-500 per 0.25 mL as either blend, because its vial is half the strength (1 mg/mL of each against 2 mg/mL). Third, GHK-Cu on its own delivers the same 2.5 mg of GHK-Cu per dose as either blend, without the repair components.
KLOW vs BPC-157 + TB-500
The two-peptide stack is the injury-only version. It omits GHK-Cu, which is the skin and matrix component and the majority of KLOW by mass, and it omits KPV. For a single tendon or ligament problem with nothing else in the picture, it is the more targeted prescription, and physicians frequently choose it over either blend for a straightforward soft-tissue injury. The comparison of its two components is at BPC-157 vs TB-500.
GHK-Cu vs GLOW
This is the comparison people search as "ghk cu vs glow." GHK-Cu on its own is the choice when skin, hair or connective-tissue quality is the whole goal and there is no injury in the picture. GLOW adds BPC-157 and TB-500 for someone with a soft-tissue complaint and a skin goal at the same time. A single agent also makes it easier to tell what is doing what, which a blend never can.
KLOW vs GLOW
Who suits which
GLOW
GLOW suits the person whose skin goal sits alongside a soft-tissue one: a slow tendon, a surgical scar, recovery that has lost pace, without inflammation as a separate complaint. It covers the repair case with one fewer component than KLOW.
KLOW
KLOW suits the same person when inflammation is a distinct part of the picture: a problem area that stays inflamed, or a background ache that never quite settles. Its rationale is that an injury which will not settle has two problems at once, an inflammatory phase that has not resolved and tissue that has not repaired.
The narrower options
Defaulting to the largest formula is the commonest mistake with these blends.
Situation What makes more sense A single tendon or ligament problem, nothing else BPC-157 + TB-500 Skin is the whole goal GHK-Cu, or RADIANCE, which pairs it with tesamorelin A gut complaint BPC-157 alone, the component with the gastrointestinal literature Inflammation that is systemic rather than local KPV alone, or FORTIFY Repair inside a longevity protocol ETERNAL, which is GLOW's three plus epithalon A complete rupture, displaced fracture or locking joint A surgical or imaging question; no peptide changes that Can you take KLOW and GLOW together?
There is no reason to. KLOW already contains everything in GLOW. Taking both would double three components, and no study informs that.
KLOW vs GLOW
What the evidence shows, honestly
There are no randomized controlled trials of KLOW, GLOW, or any combination of these components, in humans. Neither blend has been studied as a blend, in people or in animals, and no study has compared either blend with its components. The evidence is per component, and it is uneven:
| Component | Human evidence in the exports | Main preclinical work |
|---|---|---|
| GHK-Cu | Small studies of topical GHK-Cu on facial skin; a 1994 topical gel study in diabetic ulcers. No randomized trials of the injectable | Collagen synthesis in fibroblasts (FEBS Letters 1988); reviews in BioMed Research International 2015 and International Journal of Molecular Sciences 2018 |
| BPC-157 | One two-week enema study in 53 people with ulcerative colitis, reported only as a 2005 conference abstract. Nothing for the injectable route or for tendon injury | Rat Achilles tendon work in the Journal of Orthopaedic Research; tendon cell migration in the Journal of Applied Physiology (2011) |
| TB-500 | None for the fragment. Early-phase trials of the full-length thymosin beta-4 protein in dermal wounds and corneal conditions | Wound closure with thymosin beta-4 (Journal of Investigative Dermatology 1999) |
| KPV (KLOW only) | None of any kind | Mouse colitis (Gastroenterology 2008; Inflammatory Bowel Diseases 2008) |
Two cautions apply to both blends. The human skin data for GHK-Cu is topical, and no study has shown that injected GHK-Cu does what the creams are reported to do. And TB-500's literature is almost entirely on the full-length protein; the direct evidence for the fragment is much thinner. Physicians prescribe these blends on mechanism plus clinical experience. The accurate framing is "described in preclinical research and used clinically," not "shown to work in people."
KLOW vs GLOW
Where each stands with the FDA
Neither KLOW nor GLOW has a regulatory status of its own; the FDA regulates the bulk substances a pharmacy compounds from, so the question is where each component stands. As of the FDA pages checked in September 2026:
| BPC-157 | TB-500 | GHK-Cu (injectable) | KPV | |
|---|---|---|---|---|
| 2023 | Category 2 | Category 2 | Category 2 | Category 2 |
| 15 April 2026 | Removal from Category 2 announced | Removal announced | Removal announced | Removal announced |
| Advisory committee | 23 July 2026: voted 8 to 6, one abstention, to recommend the 503A Bulks List | 23 July 2026: voted 8 to 6, one abstention, to recommend | Scheduled for a meeting before the end of February 2027 | 23 July 2026: voted 8 to 6, one abstention, to recommend |
| Final FDA determination | Pending | Pending | Not yet reviewed | Pending |
In each July vote the FDA's own reviewers had recommended against inclusion, and the committee voted the other way. A committee vote is a recommendation, not a decision. None of the four components is restricted, and all remain legal to prescribe and dispense as compounded medications. Compounded medications are not FDA approved, and neither KLOW nor GLOW is an FDA-approved drug. Are peptides FDA approved explains the difference.
KLOW vs GLOW
Dosing, side by side
KLOW and GLOW are dosed identically: 0.25 mL, which is 25 units on a U-100 insulin syringe, injected under the skin (subcutaneously) on Monday through Friday mornings, with weekends off. That gives 20 doses per vial, about four weeks, which is why refills run every 28 days, one vial at a time. The proportions are fixed by the pharmacy's formulation, so every dose delivers the same split; you cannot take more of one component and less of another. If a different balance is wanted, the components are prescribed separately.
You do not need to calculate anything: your directions are printed on the vial, and your physician sets them after reviewing your intake. Abdomen and thigh are the usual sites, rotated. Both ship refrigerated with ice packs and stay in the fridge between doses, with a beyond-use date on the label. KLOW is also available as a pre-filled Pen cartridge with the same four peptides at the same totals. Technique is covered in how to inject peptides safely.
Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
KLOW vs GLOW
Side effects
Each component is generally described as well tolerated in its own published animal work, and clinical reports on both blends are consistent with that. What gets reported is mostly at the injection site: redness, mild soreness, occasional bruising. Some people report early nausea or light-headedness. GHK-Cu solutions are blue from the copper complex. KPV does not carry alpha-MSH's pigmentation effect, so darkening of skin or moles is not expected with KLOW.
There is no established interaction list for either blend, because the trials that would produce one have not been run. That is why the intake asks for every medication and supplement you take. Stop and contact your physician for any reaction that is severe, spreading, or involves difficulty breathing.
KLOW vs GLOW
Who should not take either, or should discuss it first
| Situation | Why |
|---|---|
| Wilson's disease or another copper-metabolism disorder | Both blends contain GHK-Cu, which delivers copper |
| High-dose zinc supplementation | Zinc competes with copper absorption |
| Personal history of cancer | BPC-157, TB-500 and GHK-Cu are described as supporting new blood-vessel growth |
| Anticoagulant therapy | Discuss first, given the vascular mechanisms |
| Pregnancy or breastfeeding | Not used; safety data is absent |
| Tested athletes | BPC-157 and TB-500 are named on the WADA Prohibited List |
KLOW vs GLOW
Where to get KLOW or GLOW prescribed
Neither can be bought legitimately without a prescription. Sites selling them "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested. The prescription route:
- Complete a free online intake covering your history, medications and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a state-licensed, FDA-registered US pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and dose changes.
Pepti prescribes both in all 50 states and DC. Step-by-step pages: how to get KLOW prescribed online, how to get BPC-157 + TB-500 prescribed online and how to get GHK-Cu prescribed online.
References
What this is based on.
References
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts · Molecules (2014) · PMID 25415472
- Krivic A, Anic T, Seiwerth S, et al.. Achilles detachment of rat and stable gastric pentadecapeptide BPC 157 · Journal of Orthopaedic Research (2006) · PMID 16583442
- Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract · Current Pharmaceutical Design (2011) · PMID 21548867
- Cerovecki T, Bojanic I, Brcic L, Radic B, et al.. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat · J Orthop Res (2010) · PMID 20225319
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, et al.. Stable gastric pentadecapeptide BPC 157-NO-system relation · Curr Pharm Des (2014) · PMID 23755725
- Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H · Drug Test Anal (2017) · PMID 28035768
- Thomas A, Görgens C, Guddat S et al.. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry · J Sep Sci (2016) · PMID 26578461
- Farrar JT, Young JP Jr, LaMoreaux L, Werth JL et al.. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale · Pain (2001) · PMID 11690728
- Meyer JD, Ho B, Manning MC. Effects of conformation on the chemical stability of pharmaceutically relevant polypeptides · Pharm Biotechnol (2002) · PMID 11987755
- Xu C, Sun L, Ren F, Huang P, et al.. Preclinical Safety Evaluation of Body Protective Compound-157, a Potential Drug for Treating Various Wounds · Regul Toxicol Pharmacol (2020) · PMID 32334036
- He L, Feng D, Guo H, et al.. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs · Front Pharmacol (2022) · PMID 36588717
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain · Altern Ther Health Med (2021) · PMID 34324435
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
KLOW vs GLOW, answered.
KPV. KLOW contains the same 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 as GLOW, plus 10 mg of KPV, an anti-inflammatory fragment of alpha-MSH. Everything else, including the dose and schedule, is the same.
Not in general. KLOW is the fuller formula when persistent inflammation is part of the picture; GLOW covers the repair and skin case with one fewer component. No study has compared them, and KPV has no human trials.
They deliver the same 2.5 mg of GHK-Cu per dose, which is the skin and collagen component. KPV's research is mostly in gut inflammation models and is not skin-specific, so for skin alone the two are equivalent on paper, and GHK-Cu on its own is the narrower choice.
GHK-Cu alone suits a skin, hair or connective-tissue goal with no injury involved. GLOW adds BPC-157 and TB-500 for someone with a soft-tissue complaint as well. Both deliver 2.5 mg GHK-Cu per 0.25 mL dose. GHK-Cu is $239 a month and GLOW is $259.
The stack is the injury-only version, with no GHK-Cu and no KPV, and half the BPC-157 and TB-500 per dose of KLOW. For a single tendon or ligament problem it is the more targeted prescription. Both are $259 a month.
Yes. At Pepti both are $259 a month, all-in, covering the medication, physician review, refill management and shipping.
Yes, a change of prescription is a conversation with your physician through your account. Because the doses match, the only change is that KPV is added.
It is not expected to. KPV is the fragment of alpha-MSH that keeps the anti-inflammatory signalling and drops the pigmentation effect.
There is no trial-established timeline for either. Prescribers describe little beyond injection-site tenderness in the first two weeks, with any change in a problem area or in skin developing over the following weeks and months, which is why each vial is sized at about four weeks.
No. Compounded medications are not FDA approved. All components were removed from Category 2 in April 2026; BPC-157, TB-500 and KPV were recommended for the 503A Bulks List in July 2026, and GHK-Cu is scheduled for review by February 2027. Both blends remain legal to prescribe.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.